市场调查报告书
商品编码
1541732
2024-2032 年按测试类型(巴氏检测、HPV 检测、子宫颈活检、阴道镜检查等)、年龄层(20 至 35 岁、35 岁以上)和地区分類的子宫颈癌诊断市场报告Cervical Cancer Diagnostics Market Report by Test Type (Pap Testing, HPV Testing, Cervical Biopsies, Colposcopy, and Others), Age Group (20 to 35 Years, Above 35 Years), and Region 2024-2032 |
2023年,全球IMARC Group宫颈癌诊断市场规模达80亿美元。
子宫颈癌诊断依赖一系列先进的实验室检查、工具和程序来评估异常细胞或人类乳突病毒 (HPV) 株。它们是透过采集透过锥切术、穿刺活检、子宫颈内膜刮除术和电线环获得的组织样本来进行的,以便在阴道镜检查期间对子宫颈进行彻底检查。检测后,进行血液、胸部X光、全身电脑断层扫描(CT)扫描、磁振造影(MRI)、正子断层扫描(PET)扫描以及膀胱和直肠目视检查等测试来确定疾病阶段。
被诊断患有梅毒、披衣菌、淋病和后天免疫缺乏症候群 (HIV/AIDS) 等性传染感染 (STI) 的人数大幅增加,导致全球 HPV 感染的风险不断上升。再加上吸烟者数量的增加,增加了罹患子宫颈癌的机会,这是推动市场成长的关键因素之一。此外,人们对早期诊断的认识不断提高,鼓励采用可提供快速、准确检测结果的 HPV 家庭检测试剂盒。有利的报销政策的存在也支持了市场的成长。除此之外,对个人化治疗计划的日益偏好正在增加对子宫颈癌诊断的需求。此外,一系列其他治疗方案的出现,包括手术、放射治疗、化疗、锥形活检、免疫治疗和子宫颈切除术,也促进了市场的成长。此外,对开发低成本和高效测试产品的日益重视预计将推动市场成长。
The global cervical cancer diagnostics market size reached US$ 8.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.3 Billion by 2032, exhibiting a growth rate (CAGR) of 4.8% during 2024-2032.
Cervical cancer diagnostics rely on a series of advanced laboratory tests, tools and procedures to evaluate abnormal cells or strains of the human papillomavirus (HPV). They are performed by taking a sample of the tissue obtained through conization, punch biopsy, endocervical curettage and the electrical wire loop for a thorough examination of the cervix during colposcopy. After detection, tests like blood, chest X-ray, body computed tomography (CT) scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scan and visual examination of bladder and rectum are conducted to determine the disease stage.
A considerable rise in the number of individuals diagnosed with sexually transmitted infections (STIs), such as syphilis, chlamydia, gonorrhea and acquired immune deficiency syndrome (HIV/AIDS), is escalating the risk of HPV infection worldwide. This, along with the growing number of smokers, which increases the chances of developing cervical cancer, represents one of the key factors bolstering the market growth. Furthermore, the rising awareness about early diagnosis is encouraging the adoption of HPV home testing kits that provide quick and accurate test results. The presence of favorable reimbursement policies also supports the market growth. Apart from this, rising preferences for personalized treatment plans are escalating the demand for cervical cancer diagnostics. Additionally, the availability of a range of other treatment options, including surgery, radiation therapy, chemotherapy, cone biopsy, immunotherapy and trachelectomy, is contributing to the market growth. Moreover, the growing emphasis on developing low-cost and efficient testing products is anticipated to fuel the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global cervical cancer diagnostics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on test type and age group.
Pap Testing
HPV Testing
Cervical Biopsies
Colposcopy
Others
20 to 35 years
Above 35 years
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arbor Vita Corporation, Becton, Dickinson and Company, Cooper Surgical Inc., F. Hoffmann-La Roche AG, Guided Therapeutics Inc., Hologic Inc., Qiagen, Quest Diagnostics Incorporated and Siemens Healthcare GmbH.